French drugmaker Sanofi to invest €170m to expand seasonal flu vaccine site

Ikaba Koyi WebFG News | 12 Oct, 2017 13:04 | | |

GSK, drugs, lab
  • 73.92
  • -0.82%-0.61
  • Max: 74.80
  • Min: 73.79
  • Volume: 502,430
  • MM 200 : n/a
17:36 14/12/17
  • 15,043.70
  • -0.59%-89.44
  • Max: 15,139.54
  • Min: 15,038.69
  • Volume: 0
  • MM 200 : n/a
17:45 14/12/17
  • 17,847.16
  • -0.58%-103.64
  • Max: 17,950.80
  • Min: 17,818.08
  • Volume: 0
  • MM 200 : n/a
17:45 14/12/17
  • 13,097.16
  • -0.56%-73.13
  • Max: 13,170.29
  • Min: 13,091.06
  • Volume: 0
  • MM 200 : n/a
17:45 14/12/17
  • 14,076.56
  • -0.51%-72.75
  • Max: 14,149.31
  • Min: 14,070.79
  • Volume: 0
  • MM 200 : n/a
17:45 14/12/17
  • 12,601.01
  • -0.47%-58.98
  • Max: 12,659.99
  • Min: 12,584.52
  • Volume: 0
  • MM 200 : n/a
17:45 14/12/17
  • 13,823.38
  • -0.40%-55.20
  • Max: 13,878.58
  • Min: 13,813.08
  • Volume: 0
  • MM 200 : n/a
17:45 14/12/17
  • 14,513.56
  • -0.46%-67.80
  • Max: 14,581.36
  • Min: 14,509.69
  • Volume: 0
  • MM 200 : n/a
17:45 14/12/17

French drugmaker Sanofi said it was investing €170m in effort to expand a vaccine manufacturing site in Val de Reuil, located in France, reinforcing the company's position as a global leader in seasonal flu vaccines.

The new facility, according to Sanofi, will be the only site of its kind in France and enable Sanofi Pasteur, its vaccines global business unit, to expand supply of the VaxigripTetra influenza vaccine to up to 70 countries on six continents.

That vaccine would contain two A strains and two B strains of the influenza virus, as per recommendations by the World Health Organisation, to help tackle the virus.

According to the company, the investment was one of "several major" capital expenditures that it has made in recent years to develop and expand vaccine production capacities across France, the United States and Mexico by 2021, subject to approvals by relevant health authorities.

Vaccine production in the new facility was scheduled to commence in 2022.

David Loew, the executive vice president of Sanofi and head of Sanofi Pasteur said the expansion proved the Pasteur's ability to tackle the health challenge.

"Influenza continues be a major public health problem around the world, causing serious complications, hospitalizations and deaths, mostly for certain high-risk individuals."

"As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur's ability to tackle this underestimated health challenge."

Meanwhile, Philippe Luscan, the executive vice president of Global Industrial Affairs at Sanofi spoke of the project's ability to bring together the expertise of its staff.

"This project brings together the expertise of our people with our leading industrial know-how and illustrates our commitment to manufacturing excellence solutions.

"Our investment underlines Sanofi's intent to strengthen our industrial capacities in France as a major centre of influenza vaccines production for worldwide markets."

More news

22:51 US close: Markets lower, Dow breaks winning streak

Wall Street’s main indices gave up earlier gains to close lower on Thursday, as healthcare, materials and telecoms stocks dragged investor sentiment down late in the session.

21:54 Friday preview: EU council summit conclusion, SThree and Trinity Mirror updates

The conclusion of the EU Council summit will be the main focus for markets on Friday, with no FTSE 350 companies expected to report results.

21:23 Walt Disney to buy 21st Century Fox assets in $52.4bn deal, including Sky stake

Walt Disney has announced an agreement to buy the entertainment assets of 21st Century Fox in a deal worth around $52.4bn, including a 39% stake in UK broadcaster Sky.

21:20 Scotland introduces income tax raise for top earners

The Scottish government has announced it will increase the tax paid by the country’s highest earners, as it bids to raise extra money to fund wage increases in the public sector.

20:37 Europe close: Stocks slip as traders mull ECB's next move

Stocks finished lower, tracking a weak start to trading on Wall Street and on the back of a mixed batch of economic data out of China overnight and a tweak in monetary policy by the People's Bank of China - a timely reminder perhaps of the potential ripple effects of US policy decisions and vice-versa.

18:01 London close: Footsie lower as traders test Sterling upside

London stocks finished lower on Thursday as the Bank of England stood pat on monetary policy, as widely expected, but amid dovishness across the Pond and on the other side of the Channel which resulted in a stronger Sterling.

13:18 BoE expects gradual and limited policy tightening over medium-term

The Bank of England kept policy on hold by a unanimous vote as had been widely-anticipated given previous guidance for a very gradual pace of tightening over the medium-term.

13:13 China tweaks lending rates after Fed decision

China's central bank tweaked two of its policy rates in what some analysts said was a bid to relieve pressure on the country's currency.

13:04 Google trends reveal the most searched terms of 2017

Bitcoin, the increasingly popular cryptocurrency has dominated Google’s top searches this year.

13:16 ECB keeps all rates unchanged, confirms guidance on asset purchases

The European Central Bank has opted to keep all its main policy rates unchanged, with policy-makers reiterating that they expect to keep all their key rates as they are until well past the end of the ECB's net asset purchase programme.